Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody Adjuvant Therapy for MSI-H Advanced Gastric Cancer
NCT05468138Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Aug 2022
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric cancer (GC) (3 arms), sponsored by Fudan University. Primary endpoint: Disease Free Survival at 3 years. Started Aug 2022; status: active, not recruiting.
02
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05468138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468138.